ampreloxetine
Sponsors
Theravance Biopharma Ireland Limited, Theravance Biopharma
Conditions
MSAMSA - Multiple System AtrophyNeurogenic Orthostatic HypotensionParkinson's Disease (PD)Pure Autonomic Failure (PAF)Symptomatic Neurogenic Orthostatic HypertensionSymptomatic Neurogenic Orthostatic HypotensionnOH
Phase 1
Phase 3
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
CompletedNCT03750552
Start: 2019-01-24End: 2021-07-21Updated: 2022-09-14
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
TerminatedNCT03829657
Start: 2019-02-22End: 2021-11-10Updated: 2023-01-20
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
TerminatedNCT04095793
Start: 2019-09-19End: 2021-11-12Updated: 2022-11-30
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Active, not recruitingNCT05696717
Start: 2023-06-27End: 2028-01-31Target: 102Updated: 2025-09-05
A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
Active, not recruitingCTIS2023-504876-12-00
Start: 2023-10-25Target: 33Updated: 2025-11-13